WO2001064150A1 - Transdermal patch comprising controlled heating device - Google Patents
Transdermal patch comprising controlled heating device Download PDFInfo
- Publication number
- WO2001064150A1 WO2001064150A1 PCT/US2001/006428 US0106428W WO0164150A1 WO 2001064150 A1 WO2001064150 A1 WO 2001064150A1 US 0106428 W US0106428 W US 0106428W WO 0164150 A1 WO0164150 A1 WO 0164150A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heating element
- compartment
- patch
- drag
- heating
- Prior art date
Links
- 238000010438 heat treatment Methods 0.000 title claims abstract description 419
- 229940079593 drug Drugs 0.000 claims abstract description 66
- 239000003814 drug Substances 0.000 claims abstract description 66
- 238000012377 drug delivery Methods 0.000 claims abstract description 29
- 230000002500 effect on skin Effects 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims description 45
- 239000000853 adhesive Substances 0.000 claims description 21
- 230000001070 adhesive effect Effects 0.000 claims description 21
- 238000005485 electric heating Methods 0.000 claims description 20
- 230000007246 mechanism Effects 0.000 claims description 18
- 238000001816 cooling Methods 0.000 claims description 12
- 230000000717 retained effect Effects 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 208000000003 Breakthrough pain Diseases 0.000 claims description 9
- 235000019788 craving Nutrition 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 230000035515 penetration Effects 0.000 claims description 4
- 230000000452 restraining effect Effects 0.000 claims description 4
- 230000002060 circadian Effects 0.000 claims description 2
- 230000003278 mimic effect Effects 0.000 claims 1
- 238000013271 transdermal drug delivery Methods 0.000 abstract description 8
- 238000001647 drug administration Methods 0.000 abstract 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 17
- 238000009472 formulation Methods 0.000 description 15
- 239000000463 material Substances 0.000 description 13
- 229960003604 testosterone Drugs 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 11
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 10
- 229960002428 fentanyl Drugs 0.000 description 10
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 10
- 229960002715 nicotine Drugs 0.000 description 10
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 238000007789 sealing Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000009413 insulation Methods 0.000 description 5
- 230000001839 systemic circulation Effects 0.000 description 5
- 206010057852 Nicotine dependence Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000001010 compromised effect Effects 0.000 description 4
- 239000013583 drug formulation Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- -1 antiinfectants Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 201000009032 substance abuse Diseases 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940059312 androderm Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000006261 foam material Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000009998 heat setting Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
Definitions
- the present invention is directed toward a method and apparatus for applying heat to a transdermal drug delivery system. More specifically, the invention is a securable compartment with a corresponding freely transferrable heating element for use with dermal drug delivery patches.
- transdermal delivery of certain drugs can be facilitated by the application of heat.
- Controlled heat is provided to transdermal drug delivery patches using various techniques and apparatus such as heat generating patches.
- the heat generating patches sometimes utilize heat generated from chemical reactions, such as an oxidation reaction, or may utilize heat generated by an electrical current or some other method.
- One of the disadvantages of prior art heating apparatus for the transdermal drug patches is that the heating element must be secured to the transdermal patch without compromising the transdermal drug patch's attachment to the user's skin. In other words, sometimes when a user attempts to attach, replace, or adjust a heating patch or similar device, the drug delivery patch can become dislodged or otherwise made less secure. If the drug patch is not properly situated, the drug delivery system may be compromised. It is important in transdermal drug delivery that the skin be in contact with the formulation of the drug delivery patch to achieve efficient drug transfer.
- the process of applying the heating element to the patch may cause the drug delivery patch to become less secure.
- the areas of the heating element that contain the adhesive must be pressed firmly against the heating patch to secure the heating element to the patch.
- the drug delivery system may be unintentionally compromised.
- any attempts to remove the heating element may cause the adhesive of the transdermal patch to be compromised, and thus to compromise the drug delivery.
- the continued removal and replacement of the heating element may cause the transdermal drug patch to lose enough adhesive that the drug patch does not properly contact the skin and thereby become less effective and less secure.
- a significant problem with using prior art wraps to secure a heating element to a transdermal drug patch is the potential for the heating element and/or the drug patch to become dislodged. If the heating element is secured using a wrap or tie, as the heating element is being tied to or wrapped into the user or the drag patch on the user, the process of tying or wrapping the heating element can cause the drug patch to lose contact with the skin of the patient and thereby compromise the drag delivery.
- Another disadvantage of prior art teachings is the cost of integrating a heat element with a transdermal patch, particularly for heating elements that have limited uses and applications. If a patient requires a certain level of heating in one circumstance and a different level of heating in another, then the integrated patch must be removed and an entirely different patch with an appropriate heating level must be applied. Alternatives to this would require complex patch designs that attempt to control or modify the amount of heat generated by the heating element. Thus, using an integrated patch may increase manufacturing costs significantly. Moreover, modified and integrated designs may prove to be less reliable and may be prone to misuse.
- a heating patch can be freely used with any given transdermal device, there is a potential for the patch to be abused by a patient or misused by the user.
- the patient may apply a heating element that induces an absorption rate that is too fast or delivers too much drag.
- the user may apply a heating element that fails to supply sufficient heat for a particular treatment.
- the patches do not correspond to the heating elements used with them, there is a potential for abuse or misuse.
- At least one embodiment of the present invention provides a securable heating element compartment with corresponding freely transferrable heating element.
- At least one embodiment of the present invention provides a heating element advantageously secured to a transdermal drug patch.
- At least one embodiment of the present invention provides a transdermal drug patch with a corresponding heating element pouch.
- At least one embodiment of the present invention provides a heating element that is securely attached to but freely removable from a transdermal drag delivery patch.
- At least one embodiment of the present invention provides a transdermal drug delivery patch and corresponding heating element that allows a heating element to be used to decrease the time necessary to reach steady state and that can be conveniently replaced with another heating element with different heating characteristics that provide different results,
- At least one embodiment of the present invention provides a transdermal drug delivery patch and corresponding heating element that can facilitate treatment of breakthrough pain, and/or that can be regulated to match the body's circadian rhythms, and/or that can provide additional booster drags when necessary.
- At least one embodiment of the present invention provides an electrical heating element advantageously and removably secured to a transdermal drag delivery patch.
- the present invention comprises a securable, heating element compartment with a corresponding, freely-transferrable heating element.
- the heating element compartment may be integrated with or secured to a transdermal drug delivery patch (drag patch).
- the heating element compartment provides an area of restraint that prevents the freely transferrable heating element from being displaced relative to the drag patch to which the heating element compartment is secured.
- the freely transferrable heating element limits the likelihood that a drug patch will become dislodged or displaced during the placement, transfer, or replacement of the heating element.
- the freely transferrable heating element is secured proximate to a drag patch but, nevertheless, is easily removed and replaced with use in conjunction with the heating element compartment of the present invention.
- the heating element does not require an adhesive to be secured to the drug patch, nor does it need to be wrapped or otherwise tied to the patch or patient.
- the heating element can be secured or retained in the area of restraint within the heating element compartment using the novel techniques disclosed herein, or alternatively, techniques known in the art. Novel techniques for restraining the freely transferrable heating element include using the top of the heating element compartment to provide tension and downward pressure upon a heating element within the heating element compartment.
- Tension or downward pressure may be provided by sealing at least one edge (or a portion of an edge) of the top of the heating element compartment to create an area of restraint within the compartment disposing a corresponding heating element within the heating element compartment. Because the heating element corresponds to the pouch either in relative shape or size (being approximately the same size and/or shape), the heating element fits snugly into the compartment and is secured within the heating element compartment in an area of restraint.
- the edge of the heating element compartment may be sealed and secured to a drug patch or may be sealed and secured to a bottom portion of the heating element compartment.
- the top may be integrated with the patch or may be secured to the patch or releasably secured to the patch.
- the heating element compartment also provides a physical barrier limiting relative displacement of the heating element.
- the heating element is contained within the compartment by sealing and securing at least a portion of an edge of the top. The sealed edge contains the heating element within the compartment and prevents the compartment from being unintentionally displaced out of the compartment.
- Another potential means of restraint is the use of materials that have or create sufficient frictional forces between the heating element and the heating element compartment to resist the displacement and restrain the heating element in the compartment when the heating element experiences a directional force that would otherwise displace the heating element.
- a clip or slide mechanism may be provided to restrain the heating element as shown in Figures 15 and 16. Limited adhesion or a very light weight adhesive within the heating element compartment may also provide a force, for resisting lateral displacement of the heating element.
- the heating element compartment comprises at least a top for defining the compartment and at least a portion of an edge of the top that is secured.
- the edge may be secured to a transdermal drag delivery patch (drag patch) .
- the edge may be secured, to a bottom of the heating element compartment.
- the top side of the drag patch may serve as a "bottom" for the heating element compartment; the top is secured at least along one edge (or a portion of one edge) to the transdermal drag patch.
- the top and bottom or the top and the drag patch define a heating element compartment that is secured, or is capable of being secured to or is integrated with a transdermal drag patch.
- the top is secured to the patch or alternatively, the top is secured to a bottom to form a pouch.
- the top may have a shape that corresponds to the shape and size of the heating element to facilitate the restraint of the heating element in the restraining area of the heating element compartment. As shown in Figures 1 through 20, the top may be any number of shapes and sizes. The shape of the top (as well as the heating element) may be oval, circular or semicircular, polygonal, or any other number of shapes. At least one edge or a portion of one edge of the top must be sealed to the drug patch, or in the alternative, to a bottom sheet to form a heating element compartment or a pouch.
- the top may be manufactured from any number of materials known in the art.
- the qualities of the material may affect the design of the pouch and the corresponding heating elements, and may affect or even dictate the type of treatment with which the pouch and heating element can be used.
- the top may be air permeable, air impermeable, or selectively permeable. It may be translucent, transparent, or be a particular color. The top may have inherent insulative properties or may be designed and manufactured to have enhanced insulative properties. The top and/or the compartment defined by the top may also protect and shield the heating element once the heating element is in place.
- the top may be rigid, but is preferably flexible and elastic.
- the top of the compartment can be made of a material which is air impermeable.
- the materials used to form the heating element compartment will depend in part upon the type of heating element selected. Characteristics of the pouch's constraction may vary depending upon the use of the pouch, but the pouch should be securable or integrated with the heating patch and should allow the heating element or the pouch contents to be freely transferred into or out of the pouch at a desired time.
- the heat from the heating element activates adhesive on a portion of the top, such as the entry space into the pouch, and seals the pouch when that portion is closed.
- the adhesive is deactivated and the pouch opens or is more readily opened along that portion.
- the freely transferrable heating element of the present invention is a device capable of delivering controlled heat to the transdermal drug delivery patch and/or the patient's skin
- the heating element is of a size and shape that corresponds to the securable heating element compartment.
- the freely transferrable heating element can be placed in the heating element compartment and remains secured in the area of restraint relative to the drag patch.
- the heating element compartment reduces the likelihood that the freely transferable heating element will be unintentionally dislodged until the heating element is intentionally removed from the compartment and drag patch.
- the heat from the heating element can be generated using a chemical reaction, such as an oxidation reaction, electrical heat, or other means of generating controlled thermal heat. Other methods for generating heat, such as crystallization, microwave, or infrared heat, are also contemplated.
- the heating element may provide insulation to the drug patch and skin, and may be designed to provide additional insulation to maintain a higher, controlled temperature.
- the heating element shapes and sizes may correspond to the shape and sizes of the heating element compartment and have substantially similar dimensions.
- the heating element is designed to allow the heating element to be placed within the heating element compartment with relative ease and to be removed from the compartment with relative ease, but nonetheless remains secured in the compartment to reduce the likelihood the heating element will be unintentionally displaced from the compartment or separated from the patch.
- the heating element of the present invention can provide heat for a particular duration.
- the duration of the heat may be any amount of time limited only by the ability of the battery or electric power supply to supply current to the electrical heating element.
- the electrical heating element can pulse on and off as necessary and the replacement drag patches can be supplied as frequently as necessary.
- Heating elements that use chemical reactions can be designed, manufactured to provide heat for a given duration.
- the heating element provides controlled heating. Controlled heating allows the user to provide a level of heat that results in an increase in temperature to a predetermined or prescribed range. Controlled heating is preferable to heating devices that are not controlled. If the heating element is incapable of delivering controlled heat, it becomes difficult to regulate the amount of drug being delivered, and the potential for overdose or underdose is significantly increased. Similarly, the patient's skin may be blistered or burned by uncontrolled heat. By being secured in the area of restraint within the compartment attached to the patch, the heating element provides uniform, controlled heating.
- the heating element comprises a chamber defined by air impermeable walls.
- the chamber is defined by a bottom wall, a top wall and side walls.
- the heating element preferably comprises the composition of activated carbon, iron powder, sodium chloride, water, and optionally, sawdust, which is disposed in the chamber.
- the top wall is preferably a flexible air impermeable material having a plurality of holes therethrough.
- the top wall may be an air permeable membrane or an air impermeable material with a plurality of holes.
- the top wall can have at least one covering for the plurality of holes or can have a covering to prevent air from passing through the air permeable membrane. In the embodiment having a plurality of holes in the top wall, the holes can be selectively covered and uncovered.
- the present invention can be used to increase the serum concentration of the drag delivered by the drug patch by a desired amount. For example, it may be necessary in treating a particular patient to increase the serum concentration of the drug delivered by the drag patch by 10% over the normal serum concentration as established by the drug patch's steady state.
- the present invention allows a controlled increase in temperature, which can be maintained at the increased level and if desired, returned to the original steady state level without changing the drag patch used to deliver the drug.
- the patient may find that an increase of a certain percentage is necessary for certain activities.
- a patient may need an increase in a drag serum concentration level during a period of increased physical activity or may require less drag during a period of rest.
- the present invention provides the capacity to conveniently adjust drag serum concentration levels by applying controlled heat and does so in a way that limits the chances that the drag patch will be dislodged or compromised during the application.
- the securable heating element compartment can be integrated with a specially designed drug patch, or used in conjunction with drag patches known in the art. Where the drug patch is integrated with the heating element compartment, it may be advantageous to only use a top to form the securable compartment. Where the patch is a pre-existing patch or one available in the market, the top sheet may need to be combined with a bottom sheet to form a securable heating element compartment.
- the securable heating element compartment should be of a shape and size to correspond to the specific drag patch.
- the heating element should be of a shape and size to conform or correspond to the heating element compartment and the heating element should be designed for safe and effective use with a particular type of drag patch.
- the freely transferable heating elements designed for use with transdermal fentanyl may have a particular size and shape and color.
- the colors and shapes of the heating element may be different than those for fentanyl.
- the shapes and sizes of the securable heating element compartments, and in particular the heating elements be designed and manufactured so that the compartments and heating elements designed for use with one type of drug patch are not readily useable or interchangeable with another type of drug patch.
- the color may indicate, the type of drag with which the securable compartment and heating element should be used and may also indicate the desired effect the compartment and heating element are intended to have.
- the heating element and corresponding compartment should be designed so as not to be compatible with the drag patches that could result in such harm.
- the present invention allows for heating elements and other articles to be placed proximate to a transdermal drug patch using a heating element compartment or pouch.
- the compartment or pouch could be used to retain various devices which could be advantageously placed proximate to the drag delivery patch, such as iontophoresis devices, timing devices, notification or reminder devices, any type of heating and/or cooling mechanisms, patient or patch monitoring devices, alarms, timers, watches, microprocessors, thermostats, thermometers, use indicators, and potentially and various novelty items such as toys for encouraging the use of the delivery system by children.
- Drug classes may include without limitation androgens, estrogens, nonsteroidal anti-inflammatory agents, antihypertensive agents, analgesic agents, antidepressants, antibiotics, anticancer agents, local anesthetics, antiemetics, antiinfectants, contraceptives, antidiabetic agents, steroids, anti-allergy agents, anti-migraine agents, agents for smoking cessation, and anti-obesity agents.
- Specific drags include without limitation nicotine, testosterone, estradiol, nitroglycerine, clomidine, dexamethasone, wintergreen oil, tetracaine, lidocaine, fentanyl, sufentanil, progesterone, insulin, vitamin A, vitamin C, vitamin E, prilocaine, bupivacaine, sumatriptan, dihydroergotamine, and scopolamine.
- Figure 1 shows a top view of a drag patch with a securable compartment and a freely transferrable heating element
- Figure 2 is a cross section of the drag patch with the securable compartment and freely transferrable heating element
- Figure 3 shows an embodiment of a two-sided top with at least one edge suitable for sealing
- Figure 4 shows a top having three edges with at least two edges suitable for sealing
- Figure 5 shows a four-sided top having two edges suitable for sealing
- Figure 6 shows a top having four edges with two edges suitable for sealing
- Figure 7-A shows a five-sided top with three edges suitable for sealing
- Figure 7-B shows a one-sided top with a portion of an edge suitable for sealing
- Figure 8 shows a cross section of the securable compartment with a freely transferrable heating element secured on a heating patch, the heating element and the compartment having additional insulative properties;
- Figure 9 shows a top defining an opening;
- Figure 10 shows a top defining a plurality of openings;
- Figure 11 shows a top defining an opening having a semi-permeable membrane covering said opening;
- Figure 12 shows a top that is an air permeable membrane
- Figure 13 shows a top that has additional insulative properties
- Figure 14 shows an electrically operated heating element in a securable compartment attached to a transdermal drag patch
- Figure 15 shows a top view of securable compartment having attachment clips
- Figure 16 shows a top view of a securable compartment having attachment clips in which the disk is held in place by the clips;
- Figure 17 is a partial cutaway of a securable compartment with a freely transferrable heating element retained in an area of retaining secured to a drug delivery patch;
- Figure 18 shows one embodiment of an electric heating element
- Figure 19 shows an embodiment of an exothermic heating element
- Figure 20 shows another embodiment of the present invention.
- the present invention comprises a drag delivery patch 60, a securable heating element compartment 80, and a freely transferrable heating element 100 retained in compartment 80.
- the drug patch 60 with a heating element compartment 80 and an electric heating element 100, is placed upon the skin of a patient in need of transdermal delivery of a drag where heating element 100 delivers controlled heat to the patient' s skin and the drag formulation and the drug delivery patch 60.
- the controlled heat increases the absorption of the drag through the skin into the systemic circulation of the patient. Controlled heat on the patient's skin and drag patch 60 results in an increased absorption rate that allows the patient to obtain a steady state concentration in the systemic circulation more quickly than the patient could without the heating element.
- heating element 100 may be removed, but is preferably left inside securable heating element compartment 80 in order to provide insulation to the administration site.
- Heating element 100 can be replaced with another freely transferable heating element 100 if necessary in order to provide additional heat.
- the additional heat may be provided to further increase the concentration level of the steady state, or alternatively, may be provided to give the patient additional drug beyond a desired steady state.
- original heating element 100 can be replaced by a different kind of heating element 100, if necessary, and a different level of controlled heat may be applied to the patient's skin, the dermal drag patch 60, and the drug formulation in order to cause a sharp increase in the drag concentration above the steady state.
- controlled heating of the heating element is provided by an oxidation reaction.
- the heating element 100 comprises side wall 106 defined by a 1 /8 inch thick rectangular foam tape (2 layers of No.1779 1/16" white foam tape, 3M Corporation, Minneapolis, Minnesota, USA) with an outer dimension of about 2.25 inches by 4 inches with an opening therein having an inner dimension of about 1.75 inches by 3.5 inches, a bottom wall 102 comprising rectangular medical tape (No.
- top wall 104 may be covered by an air permeable membrane 116 comprising a porous membrane (No.9711 microporous polyethylene film - CoTranTM, 3M Corporation, Minneapolis, Minnesota, US A) disposed between the top wall 104 and the temperature regulating mechanism 108.
- air permeable membrane 116 comprising a porous membrane (No.9711 microporous polyethylene film - CoTranTM, 3M Corporation, Minneapolis, Minnesota, US A) disposed between the top wall 104 and the temperature regulating mechanism 108.
- Side wall 106, bottom wall 102, and top wall 104 all have 1/8" rounded corners.
- Heat generating component 108 disposed in the chamber comprises a mixture of activated carbon (HDC grade - Norit Americas, Inc., USA), iron powder (grade R1430 - ISP Technologies, USA), saw dust (Wood Flour, Pine - Pioneer Sawdust, USA), sodium chloride and water in the weight ratio of approximately 5:16:3:2:6 weighing approximately 16.5 grams. Heating element 100 is sealed in an air-tight container immediately after fabrication.
- activated carbon HDC grade - Norit Americas, Inc., USA
- iron powder grade R1430 - ISP Technologies, USA
- saw dust Wood Flour, Pine - Pioneer Sawdust, USA
- sodium chloride sodium chloride
- the invention entails the integral attachment of heating element compartment 80 (or pouch 80) to the top side of a transdermal drag delivery patch 60 for the purposes of affixing controlled heating element 100, such as a heating disc 100, to drug patch 10.
- Drag patch 60 may be a reservoir or matrix (monolith) patch.
- the compartment or pouch 80 is formed by securing a heating element compartment top
- Top 82 to a drug patch 60.
- Top 82 has at least one edge 84 with at least a portion 86 of edge 84 being secured or sealed to drag patch 60.
- Pouch 80 may be made of a variety of materials. Top 82 of pouch 80 may be attached to drag patch 60 along at least portion 86 of edge 84 by any of several means such as heat-sealing, RF- welding, or the use of any variety of adhesive.
- Pouch 80 is used to house or contain heating element 100, (such as a disposable, air-activated, chemical heating or disc to enhance the delivery of drags through the skin manufactured by ZARS) holding the heating element 100 in direct contact with drug patch 60.
- Pouch 80 defines at least one opening 90 or a number of smaller openings 90 across its surface in order to allow oxygen to enter and activate heating element 100.
- transdermal drag patch 60 may be any of a number of drags, such as, but not limited to, fentanyl, testosterone, estradiol, scopolamine, nicotine, nitroglycerin, local anesthetics etc.
- Transdermal drag patch 60, attached pouch 80, top may be any of a number of drags, such as, but not limited to, fentanyl, testosterone, estradiol, scopolamine, nicotine, nitroglycerin, local anesthetics etc.
- heating element 100 may be any of a variety of different shapes, such as, but not limited to, a square, rectangular, circular, oval, triangular, as shown in Figures 1-20.
- heating elements 100 with different heating characteristics can provide important advantages in treatments. For example, with the transdermal delivery of fentanyl, the application of a 4-hour heating element with a temperature of 42-
- heating elements 100 or discs 100 are useful in conjunction with the transdermal fentanyl patch 60; one for reducing the onset time to steady-state levels and one for combating breakthrough pain. Heating elements 100 of different sizes and shapes and different heating temperatures and durations may be housed in marsupial pouch 80.
- Heating patches 100 or discs 100 may be color-coded in order to indicate different heating temperatures and durations for different uses.
- the onset heating element 100 might maintain a temperature of 42-44 °C for 4-hours and might be blue.
- the breakthrough heating element 100 might maintain a temperature of 42-44°C for 5-20 minutes and might be green.
- fentanyl patch 60 may be packaged with a blue onset heating element 100 already housed in marsupial pouch 80. Thus, when patch 60 is applied, the heating begins and a shorter onset time to steady-state is achieved.
- heating element 100 may be left in marsupial pouch 80 in order to provide a level of insulation, which may protect drag patch 60 from variations in ambient temperature. Later on, when an episode of breakthrough pain is experienced, blue onset heating element 100 may be removed from marsupial pouch 80 and a green breakthrough heating element 100 may be inserted into pouch 80. As heating element 100 dies out on its own after its prescribed heating duration, it is not necessary to remove it at specified time intervals. Rather, heating element 100 may be left in marsupial pouch 80, if desired, until a new breakthrough heating element 100 is needed.
- marsupial pouch 80 Since marsupial pouch 80 is directly attached to transdermal drag patch 60, there is no need to use adhesive to attach heating element 100 to drag patch 60, which would increase the likelihood of removing drag patch 60 upon removal of the heating element 100.
- Marsupial pouch 80 provides excellent contact between heating element 100 and drag patch 60.
- Marsupial pouch 80 limits the risk of abuse of heating patch 60 with other drag patches for which it is not indicated and with which it has not been studied.
- heating elements 100, or discs 100 are preferably not adhesive, they cannot be used with any drug patch, but only with those that have a corresponding pre-attached marsupial pouch 80 for housing drag patch 60.
- Marsupial pouch 80 simplifies the process of using several different types of heating elements 100 (for example, onset and breakthrough elements) since it is simple and easy to remove and replace heating elements 100.
- Heating elements 100 may have a tab on one end to facilitate easy insertion and removal.
- Example 1 an embodiment of the present invention is used for dermally administrating nicotine for suppressing a patient's nicotine cravings.
- a user (a patient or caregiver) administers a nicotine patch 60 with a freely transferrable heating element 100 in a heating element compartment 80 secured to patch 60. After just a few hours, the patient should obtain a steady state nicotine concentration in the blood stream sufficient to suppress a baseline nicotine craving.
- the user replaces freely transferrable heating element 100 with a second, different transferrable heating element 100, the second heating element having different heating characteristics.
- Second heating element 100 may use an exothermic reaction to generate heat.
- the heat created by second heating element 100 lasts for at least 15 minutes before the exothermic reaction exhausts second heating element 100.
- the heat increases the transport of nicotine across the skin and increases the blood flow in the tissues under nicotine patch 60, which carries the nicotine stored in tissues under patch 60 into the systemic circulation at increased rates.
- the patient gets a rapid increase in blood nicotine concentration to treat the surge of the nicotine craving.
- the absorption rate gradually declines to deliver the steady state nicotine concentration in the blood stream.
- Example 2 Another example of using an embodiment of the present invention for dermally administering testosterone to increase and optimize the amount of drag delivered comprises a user placing a testosterone patch 60, such as a one day dermal testosterone patch (EG Androderm ® produced by TheraTech, Inc. of Salt Lake City, Utah, USA) on the skin of the patient. Patch 60 can be applied to the skin at night, for example, around 10:00 p.m. However, in order to raise the steady state concentration of the testosterone quickly, the user may apply a freely transferrable heating element 100 to a heating element compartment 80 secured to testosterone patch 60. Heating element 100 is designed to provide heat for a desired period of time in order to allow the serum concentration of testosterone to reach a steady state more rapidly than it would without heating element 100. Whenheat from heating element 100 is terminated, heating element
- 100 may provide a measure of insulation to maintain an increased level of absorption from patch 60 or may be freely removed from compartment 80.
- Testosterone patch 60 can be worn or applied at night, for example, around 10:00 p.m. However, if the patient does not get a sufficient dosage of testosterone by the next day, the user can apply a second, different heating element 100 into secured compartment
- Second heating element 100 can provide increased temperature to patch 60 and the skin and the tissues under the skin and thereby significantly increase the absorption of testosterone. Additionally, the heat may promote the effectiveness of a permeation enhancer in the drag formulation of patch 60. The ultimate result is that the patient gets sufficient testosterone from patch 60 in an efficient manner. The efficient use of heating element 100 may allow the reduction of permeation enhancer concentration in the drag formulation of patch 60. Permeation enhancers are sometimes associated with significant skin irritation.
- Example 3 The present invention can also be used to administer a drag transdermally that otherwise would have a diffusion coefficient or a permeability coefficient across a rate limiting membrane 62 of patch 60 that would be disadvantageous ⁇ low.
- a user places a patch containing a drug onto the skin of the patient and after waiting for a period of time determines that the administration requires a higher concentration of drug in the patient's blood stream to properly treat the patient's condition.
- the user can remove freely transferrable heating element 100 and replace it with a second, different freely transferrable heating element 100 having heating characteristics that facilitate increased absorption of the drag.
- Increased temperature provided by second heating element 100 may increase the diffusion coefficient of the active ingredient in the formulation and/or increase the permeability coefficient of the drug across the rate limiting membrane of patch 60.
- the overall rate at which the active ingredient enters the body would thereby also increase and in turn, increase the concentration of the active ingredient in the patient's blood stream.
- Example 4 The present invention can be used to decrease the onset time of a drug from a transdermal drug patch 60.
- a user places patch 60 on a patient's skin.
- Patch 60 contains a freely transferrable heating element 100 secured in heating element compartment 100 on patch 60.
- the heat allows the drag formulation in transdermal drag patch 60 to be absorbed more quickly through the skin.
- the user can replace the initial heating element 100 with a second, different freely transferrable heating element 100 having different heating characteristics, for example, generating higher temperatures.
- the increased temperature allows the drag to be absorbed into the patient's systemic circulation more quickly and if sustained over a sufficient amount of time results in a quicker onset of the drag.
- second heating element 100 with the higher temperature can be left in place for insulative effect or removed or replaced with a heating element 100 that allows patch 60 to deliver the drug at a more typical steady state.
- the important advantage provided by this approach is that the onset time of patch 60 can be shortened without significantly altering the patch's steady state delivery rate.
- Drag patch 60 contains a freely transferrable heating element 100 in a heating element compartment 100 secured to patch 60. Patch 60 heats the patient's skin and heating element 100 for a period of time. The drug from transdermal patch 60 is absorbed into the tissues beneath and proximate to drag patch 60. Heating element 100 facilitates the absorption of the drug into the tissue.
- heating element 100 can be removed and replaced with a second, different freely transferrable heating element 100, which provides different heating characteristics, such as increased duration or increased temperature. For example, as second heating element 100 increases the temperature of the drag formulation and the tissues around drug patch 60, the heat drives the drag further into the skin and allows for deeper penetration. If desired, after the drug has reached a penetration level sufficient for the treatment, second heating element 100 can be removed and replaced with the original heating element 100 or another freely transferrable heating element 100 having heating characteristics more suited toward delivering a drag at a desired rate.
- Example 6 Another example of the present invention comprises replacing an original heating element 100 with a second, different heating element 100 to increase solubility of the drug in formulation.
- a drug delivery patch 60 may have a drag formulation with a certain solubility of the drag in the drag formulation.
- the solubility rate may be appropriate for a given treatment and provide the drag to the skin for absorption at a particular desired rate.
- Solubility of the drag may be dependent upon the heat applied to the drag formulation by an initial freely transferrable heating element 100.
- initial heating element 100 can be removed and replaced with a second, different, freely transferrable heating element 100 that provides different heating characteristics. Second heating element 100 may generate increased heat so that the solubility of the drag in the drug formulation is higher.
- Example 7 Because the increased temperature increases the solubility of the drag compound in the formulation, more drag compound can be dissolved in the formulation, which may yield a higher driving force for the transdermal permeation of the drug compound. Ultimately, more of the drug can enter the patient's systemic circulation.
- Figure 18 illustrates an electric heating element 200 comprising an electric heating element 202 surrounded by a bottom wall 102, a top wall 104, and side walls 152
- the side walls 152 preferably, extend a distance below the bottom wall 102 to define a cavity 154. It is understood that the electric heating element 202 does not have to have the side walls 152 forming a cavity 154.
- the bottom wall 102 and the side walls 152 are preferably made of a flexible non- air permeable material, such as non-air permeable closed-cell foam material.
- a portion of the bottom of the heating element 200 includes an adhesive material 112 on the bottom of the side walls 152 and, preferably, includes a second adhesive material 156 in the bottom of the bottom wall 102, wherein the second adhesive material 156 is preferably less adhesive than the adhesive material 112.
- the electric heating element 202 preferably comprises a flexible resistor plate that can generate heat when supplied with an electric current through traces 206, 208.
- the electric current is preferably supplied from a battery 212 attached to a control mechanism 214, and an electronic switch 216.
- the battery 212, the control mechanism 214, and the electronic switch 216 are preferably attached to the top surface of the top wall 104.
- the electric heating element 202 is activated by triggering the electronic switch 216 which begins the flow of electric current from the battery 212 to the electric heating element 202.
- a temperature sensor 218, such as a thermistor, is preferably attached to the bottom of the bottom wall 102 and sends a signal (corresponding to the temperature at the bottom of the bottom wall 102) through electric trace 222 to the control mechanism 214.
- the control mechanism 214 regulates the flow of current to the electric heating element 202, so that the electric heating element 202 quickly brings the temperature at a contact surface between the bottom wall 102 and a top of a drug patch (not shown) to a pre-determined level and maintains the temperature at that pre-determined level.
- control mechanism 214 1) a mechanism that allows a physician or care giver set the length of each heating period for each patient, which allows the physician to limit the heating, and hence the extra drug that the patient can get based on the conditions of the patient; 2) a mechanism that allows the physician or care giver to set the minimum time between the heating periods, and hence how often the patient can get the extra drug through increase heat; 3) a mechanism that allows the physician or care giver to set a pre-determined temperature; and/or 4) a mechanism that allows the physician or care giver to control the heating temperature profile, such as gradually increasing heating temperature or decreasing temperature over a pre-determined period of time.
- the heating element can be freely transferable into and out of a heating element compartment or pouch.
- Battery 212, control mechanism 214, and electric switch 216 may be attached to the heating element or the drag delivery patch to which the heating element is secured.
- battery 212 and control mechanism 214 may be worn separately.
- a detached battery 212 and control mechanism 214 are shown in Figure 14.
- electric heating compartment 202 may be activated by the automatic triggering of electronic switch 216 and allowing a flow of electric current from the battery through the heating element. Temperature sensor 218 that provides precise regulation of the heat generated in the heating element may also provide an additional control mechanism for the duration of the heat generated by electric heating element 200.
- the electric heating element can be combined with a microprocessor 230 to provide highly accurate and highly regulated temperature control. For example, microprocessor 230 can regulate when the heating element 200 is turned on, its temperature, and when heating element 200 is turned off. Electric heating element 200 can be freely transferred from heating element compartment 80 secured to patch 60 and replaced with different electric heating element 200 or some other heating elements 100.
- Example 8 One of the distinct advantages of the present invention is the ability to use various types of heating elements 100 to generate heat for the delivery of the drag through transdermal patch 60.
- a patient may have applied a dermal drag delivery patch 60 with a freely transferable heating element retained in a compartment secured to the patch.
- Heating element 100 may be an electric heating element 200 having an electric current supplied by a battery 212. In the event that the electric heating element
- electric heating element 200 malfunctions or battery 212 for the patch runs out of current, electric heating element 200 can be easily removed and replaced with a different electrical heating element 200 or with a different heating element 100, such as a heating element using heat generated from an exothermic chemical reaction.
- the ability to change from electrical to exothermic chemically generated heat may be particularly advantageous where the activities of the patient prohibit or make impractical the use of a given type of heating element.
- the patient may replace the electrical heating element with the exothermic chemical heating element or some other type of heating element 100.
- a dermal drag delivery system comprises a heating element structure 302 releasably secured to a patient's skin.
- the heating element structure comprises a heating element 300 and a top side 304 having at least a portion of an edge secured to the skin or alternatively secured to a bottom side that is secured to the skin. Alternatively, at least two walls extending from the top side toward the bottom side may be attached to a patient's skin.
- Heating element structure 302 defines a compartment in which is provided an area of containment beneath the bottom side of the heating element 300.
- a freely transferable drag delivery patch 310 may be placed into the compartment beneath heating element 300.
- the drug delivery patch 310 is secured in the area of containment and maintains contact with the patient' s • skin to deliver the drug in the drag patch 310. Heat from heating element 300 is used as disclosed in the application to improve the administration of the drag from drag patch 310.
- heating element structure 302 forms a drag delivery patch compartment and provides heat to drug delivery patch 310.
- heating element 300 is connected to a microprocessor, a wide variety of drag delivery patches can be used in combination with heating element 300, which can be adjusted and programmed to provide heat at desired times and for desired durations in accordance with the drag being used.
- Patch 310 that is used with heating element 300 could be designed to have identification information on patch 310 that indicates to the user the appropriate heat settings for heating element 300. Through the use of the microprocessor identification information is read by a reading device such as an optical scanner and the microprocessor automatically sets appropriate heating levels.
- Example 10 Another example of the present invention comprises inserting a device other than a freely transferable heating element into the drag delivery pouch.
- the heating element compartment provides the user the opportunity to place various devices proximate to the heating patch which can assist in dermal drag delivery.
- an iontophoresis device can be secured to a heating patch using the pouch of the present invention.
- the iontophoresis device can apply a positive current from an electrode to a drag formulation on the skin that will drive positively- charged ions away from the electrode and into the skin.
- a negative current can be applied to influence negatively-charged ions.
- Current variations from the iontophoresis device will influence and increase the iontophoretic effect in drag delivery.
- an iontophoresis device can be placed in the heating element compartment in place of the heating element.
- Example 11 The present invention is not limited to devices which increase temperature.
- a cooling element may likewise decrease the temperature or cool the drug formulation, the drag delivery patch, and the patient's skin. Cooling the patient's skin may slow drag delivery in a manner that is advantageous for a given treatment.
- the present invention can be used to increase the onset time of the drag from a transdermal drag patch 60.
- a user places patch 60 on a patient's skin.
- Patch 60 contains a freely-transferrable cooling element 100 secured in cooling compartment 100 on patch 60.
- the cooling element 100 is capable of cooling the drag patch 60 and the patient's skin.
- the cooling effect on the drug formulation in the drag patch 60 slows the absorption of the drag through the patient's skin. By slowing the absorption from the drug patch 60, the cooling element 100 reduces the serum concentration level and thereby increases the onset time of the drag.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01911203A EP1267764A4 (en) | 2000-02-29 | 2001-02-28 | Transdermal patch comprising controlled heating device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/515,722 US6261595B1 (en) | 2000-02-29 | 2000-02-29 | Transdermal drug patch with attached pocket for controlled heating device |
US09/515,722 | 2000-02-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001064150A1 true WO2001064150A1 (en) | 2001-09-07 |
Family
ID=24052472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/006428 WO2001064150A1 (en) | 2000-02-29 | 2001-02-28 | Transdermal patch comprising controlled heating device |
Country Status (3)
Country | Link |
---|---|
US (2) | US6261595B1 (en) |
EP (1) | EP1267764A4 (en) |
WO (1) | WO2001064150A1 (en) |
Families Citing this family (244)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040265353A1 (en) * | 1995-07-28 | 2004-12-30 | Zars, Inc. | Systems and methods for treating panic attacks |
US20020114827A1 (en) * | 1995-07-28 | 2002-08-22 | Jie Zhang | Methods and apparatus for improved administration of analgesics |
US8182473B2 (en) | 1999-01-08 | 2012-05-22 | Palomar Medical Technologies | Cooling system for a photocosmetic device |
US6273884B1 (en) | 1997-05-15 | 2001-08-14 | Palomar Medical Technologies, Inc. | Method and apparatus for dermatology treatment |
US6517532B1 (en) | 1997-05-15 | 2003-02-11 | Palomar Medical Technologies, Inc. | Light energy delivery head |
AU3450799A (en) | 1998-03-12 | 1999-09-27 | Palomar Medical Technologies, Inc. | System for electromagnetic radiation of the skin |
US6726673B1 (en) * | 1999-05-24 | 2004-04-27 | Zars, Inc. | Methods and apparatus for improved administration of testosterone pharmaceuticals |
US7897140B2 (en) | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
US6261595B1 (en) * | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
US20020106407A1 (en) * | 2000-12-11 | 2002-08-08 | Dennis Coleman | Method and apparatus for treating breakthrough pain |
IL157684A0 (en) * | 2001-03-02 | 2004-03-28 | Palomar Medical Tech Inc | Apparatus and method for photocosmetic and photodermatological treatment |
KR20030087657A (en) | 2001-03-27 | 2003-11-14 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism |
US20050054730A1 (en) * | 2001-03-27 | 2005-03-10 | The Regents Of The University Of California | Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha |
AU2002322720B2 (en) * | 2001-07-25 | 2008-11-13 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
DE10141650C1 (en) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate |
US7349733B2 (en) * | 2001-11-02 | 2008-03-25 | Ceramatel, Inc. | Iontophoretic drug delivery systems |
US7354448B2 (en) | 2001-11-29 | 2008-04-08 | Palomar Medical Technologies, Inc. | Dental phototherapy methods and compositions |
JP2006506317A (en) | 2002-01-11 | 2006-02-23 | バイオマリン ファーマシューティカル インコーポレイテッド | Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
US6775570B2 (en) * | 2002-02-04 | 2004-08-10 | Ceramatec, Inc. | Iontophoretic treatment device |
US7047069B2 (en) | 2002-02-04 | 2006-05-16 | Ceramatec, Inc. | Iontophoretic fluid delivery device |
KR20050026404A (en) | 2002-06-19 | 2005-03-15 | 팔로마 메디칼 테크놀로지스, 인코포레이티드 | Method and apparatus for photothermal treatment of tissue at depth |
EP1517684B1 (en) | 2002-06-27 | 2009-07-22 | Health Research, Inc. | Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy |
CA2491661A1 (en) * | 2002-07-12 | 2004-01-22 | Biomarin Pharmaceutical Inc. | The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
JP4515911B2 (en) | 2002-10-07 | 2010-08-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Modulation of anxiety by blocking anandamide hydrolysis |
EP1558339A1 (en) * | 2002-10-07 | 2005-08-03 | Palomar Medical Technologies, Inc. | Apparatus for performing photobiostimulation |
US20070213792A1 (en) * | 2002-10-07 | 2007-09-13 | Palomar Medical Technologies, Inc. | Treatment Of Tissue Volume With Radiant Energy |
US7765162B2 (en) * | 2002-10-07 | 2010-07-27 | Mastercard International Incorporated | Method and system for conducting off-line and on-line pre-authorized payment transactions |
EP2522294A2 (en) | 2002-10-23 | 2012-11-14 | Palomar Medical Technologies, Inc. | Phototreatment device for use with coolants and topical substances |
US7483738B2 (en) * | 2002-11-29 | 2009-01-27 | Power Paper Ltd. | Combination stimulating and exothermic heating device and method of use thereof |
US6893453B2 (en) * | 2002-12-17 | 2005-05-17 | Kimberly-Clark Worldwide, Inc. | Thermal therapy pad with variable heat control |
AU2003301111A1 (en) * | 2002-12-20 | 2004-07-22 | Palomar Medical Technologies, Inc. | Apparatus for light treatment of acne and other disorders of follicles |
PL378076A1 (en) * | 2003-02-07 | 2006-02-20 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system suitable for heat application for promoting the permeation of active substances, and the use thereof |
AU2004213047A1 (en) * | 2003-02-19 | 2004-09-02 | Palomar Medical Technologies, Inc. | Method and apparatus for treating pseudofolliculitis barbae |
US20040191301A1 (en) * | 2003-03-27 | 2004-09-30 | Van Duren Albert Philip | Transdermal device having a phase change material |
BRPI0410348A (en) * | 2003-05-14 | 2006-05-30 | Torreypines Therapeutics Inc | compounds and uses thereof in amyloid-beta modulation |
US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
AU2004253471B2 (en) | 2003-06-20 | 2010-05-13 | Raptor Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
JP2007509066A (en) * | 2003-10-16 | 2007-04-12 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Food and other compositions, compounds and methods for reducing body fat, suppressing appetite and regulating fatty acid metabolism |
US7211070B2 (en) * | 2003-12-01 | 2007-05-01 | Abraham Ebbie Soroudi | Device and method for exothermic treatment of eyelid diseases |
US7867511B2 (en) | 2004-01-23 | 2011-01-11 | Travanti Pharma Inc. | Abuse potential reduction in abusable substance dosage form |
US8535711B2 (en) * | 2004-01-23 | 2013-09-17 | Teikoku Pharma Usa, Inc. | Medication disposal system |
US20050167438A1 (en) * | 2004-02-02 | 2005-08-04 | Max Minyayev | Secure spill-proof configuration for child training cup |
WO2005090370A1 (en) * | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
US20080014188A1 (en) * | 2004-02-06 | 2008-01-17 | Zankel Todd C | Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof |
US7513893B2 (en) * | 2004-03-12 | 2009-04-07 | Abraham Ebbie Soroudi | Device and method for treatment of eyelid diseases |
US20080132886A1 (en) * | 2004-04-09 | 2008-06-05 | Palomar Medical Technologies, Inc. | Use of fractional emr technology on incisions and internal tissues |
EP1748740A4 (en) * | 2004-04-09 | 2008-12-31 | Palomar Medical Tech Inc | Methods and products for producing lattices of emr-treated islets in tissues, and uses therefor |
WO2005112913A1 (en) | 2004-05-20 | 2005-12-01 | The Scripps Research Institute | Transthyretin stabilization |
GB0412793D0 (en) * | 2004-06-09 | 2004-07-14 | Boots Healthcare Int Ltd | Therapeutic product |
US20060135773A1 (en) * | 2004-06-17 | 2006-06-22 | Semple Joseph E | Trisubstituted nitrogen modulators of tyrosine phosphatases |
WO2006017124A2 (en) * | 2004-07-09 | 2006-02-16 | Cengent Therapeutics, Inc. | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases |
US7537590B2 (en) | 2004-07-30 | 2009-05-26 | Microchips, Inc. | Multi-reservoir device for transdermal drug delivery and sensing |
EP1841749A1 (en) * | 2004-09-02 | 2007-10-10 | Metabasis Therapeutics, Inc. | Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
DE102004044578A1 (en) | 2004-09-13 | 2006-03-30 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with an adhesive layer, method for siliconizing a backing layer of the system and use of the backing layer |
EP1802258A4 (en) | 2004-09-13 | 2015-09-23 | Chrono Therapeutics Inc | Biosynchronous transdermal drug delivery |
NZ588431A (en) | 2004-09-17 | 2012-02-24 | Whitehead Biomedical Inst | Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity |
CA2591092A1 (en) * | 2004-12-17 | 2006-06-22 | Alza Corporation | Temperature modulation of transdermal drug delivery |
US8222257B2 (en) | 2005-04-01 | 2012-07-17 | The Regents Of The University Of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
US20090156545A1 (en) * | 2005-04-01 | 2009-06-18 | Hostetler Karl Y | Substituted Phosphate Esters of Nucleoside Phosphonates |
CA2503456A1 (en) * | 2005-04-05 | 2006-10-05 | Imre Virag | Multi purpose cartridge system for delivery of beneficial agents |
US7856985B2 (en) | 2005-04-22 | 2010-12-28 | Cynosure, Inc. | Method of treatment body tissue using a non-uniform laser beam |
US20060243809A1 (en) * | 2005-04-27 | 2006-11-02 | Hodgson Rodney T | Combination logo and identification code |
WO2007002109A2 (en) * | 2005-06-20 | 2007-01-04 | The Regents Of The University Of California | Multidentate pyrone-derived chelators for medicinal imaging and chelation |
JPWO2007010900A1 (en) * | 2005-07-15 | 2009-01-29 | Tti・エルビュー株式会社 | Patch for percutaneous absorption with ion position display function and iontophoresis device |
US7793666B2 (en) * | 2005-07-28 | 2010-09-14 | Innovation Biomedical Devices, Inc. | Apparatus and method for treatment of infected nail |
CN101282692A (en) * | 2005-08-08 | 2008-10-08 | 帕洛玛医疗技术公司 | Eye-safe photocosmetic device |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
CA2622560A1 (en) | 2005-09-15 | 2007-03-29 | Palomar Medical Technologies, Inc. | Skin optical characterization device |
US9062126B2 (en) | 2005-09-16 | 2015-06-23 | Raptor Pharmaceuticals Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof |
WO2008051197A2 (en) * | 2005-09-20 | 2008-05-02 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
US20070106353A1 (en) | 2005-11-08 | 2007-05-10 | Carstens Jerry E | Body conforming shirt-like holder and thermal article |
US8099794B2 (en) | 2005-12-19 | 2012-01-24 | Rusl, Llc | Body conforming textile holder for electronic device |
BRPI0709699A2 (en) * | 2006-03-29 | 2011-07-26 | Foldrx Pharmaceuticals Inc | inhibition of alpha synuclein toxicity |
US7586957B2 (en) | 2006-08-02 | 2009-09-08 | Cynosure, Inc | Picosecond laser apparatus and methods for its operation and use |
EP2064243A2 (en) | 2006-08-28 | 2009-06-03 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic human light-specific human monoclonal antibodies |
MX2009002893A (en) | 2006-09-18 | 2009-07-10 | Raptor Pharmaceutical Inc | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates. |
PL2124556T3 (en) | 2006-10-09 | 2015-02-27 | Charleston Laboratories Inc | Pharmaceutical compositions |
WO2008074005A1 (en) * | 2006-12-13 | 2008-06-19 | Palomar Medical Technologies, Inc. | Cosmetic and biomedical applications of ultrasonic energy and methods of generation thereof |
US20080177219A1 (en) * | 2007-01-23 | 2008-07-24 | Joshi Ashok V | Method for Iontophoretic Fluid Delivery |
US20080208162A1 (en) * | 2007-02-26 | 2008-08-28 | Joshi Ashok V | Device and Method For Thermophoretic Fluid Delivery |
WO2009081262A1 (en) | 2007-12-18 | 2009-07-02 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
US9220837B2 (en) | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
US8622991B2 (en) | 2007-03-19 | 2014-01-07 | Insuline Medical Ltd. | Method and device for drug delivery |
MX2009010000A (en) | 2007-03-19 | 2010-03-17 | Insuline Medical Ltd | Drug delivery device. |
JP2010524849A (en) * | 2007-03-21 | 2010-07-22 | ラプトール ファーマシューティカル インコーポレイテッド | Cyclic receptor-related protein peptide |
WO2008154000A1 (en) * | 2007-06-08 | 2008-12-18 | Cynosure, Inc. | Thermal surgery safety suite |
US8197844B2 (en) | 2007-06-08 | 2012-06-12 | Activatek, Inc. | Active electrode for transdermal medicament administration |
US20090264421A1 (en) * | 2007-10-05 | 2009-10-22 | Bible Keith C | Methods and Compositions for Treating Cancer |
NZ583970A (en) | 2007-10-11 | 2011-04-29 | Univ California | Compositions and methods of inhibiting n-acylethanolamine-hydrolyzing acid amidase |
CA2706465A1 (en) | 2007-11-21 | 2009-05-28 | Pharmaxis Ltd. | Haloallylamine inhibitors of ssao/vap-1 and uses therefor |
EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
US8862223B2 (en) | 2008-01-18 | 2014-10-14 | Activatek, Inc. | Active transdermal medicament patch and circuit board for same |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US20090326447A1 (en) * | 2008-06-27 | 2009-12-31 | Joshi Ashok V | Transdermal Delivery Apparatus and Method |
US11016104B2 (en) | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
TW201026347A (en) * | 2008-09-10 | 2010-07-16 | Transcu Ltd | Apparatus and method to dispense HPC-based viscous liquids into porous substrates, e. g., continuous web-based process |
US20100075532A1 (en) * | 2008-09-25 | 2010-03-25 | Tyco Healthcare Group Lp | Fluorescent Marker for Detecting Gel or Lack of Gel |
US20100072060A1 (en) * | 2008-09-25 | 2010-03-25 | Tyco Healthcare Group Lp | Biomedical Electrode and Method of Formation Thereof |
US20100076294A1 (en) * | 2008-09-25 | 2010-03-25 | Tyco Healthcare Group Lp | System and Method of Prepping Skin Prior to Electrode Application |
BRPI0916125A2 (en) | 2008-11-07 | 2015-11-03 | Insuline Medical Ltd | "treatment device" |
US9012477B2 (en) * | 2009-01-06 | 2015-04-21 | Nuvo Research Inc. | Method of treating neuropathic pain |
AU2010203709B2 (en) | 2009-01-06 | 2014-05-22 | Galenagen, Llc | Compositions and methods for the treatment or prevention of Staphylococcus Aureus infections and for the Eradication or reduction of Staphylococcus Aureus on surfaces |
CA2747703C (en) | 2009-01-06 | 2021-06-15 | Curemark Llc | Compositions and methods for the treatment or the prevention of infections by e. coli |
JP4934163B2 (en) * | 2009-03-18 | 2012-05-16 | オカモト株式会社 | Skin laminate |
EP2413837A4 (en) * | 2009-04-01 | 2013-10-23 | Jie Zhang | Methods for treating myofascial, muscle, and/or back pain |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US9186334B2 (en) | 2009-05-04 | 2015-11-17 | Nuvo Research Inc. | Heat assisted lidocaine and tetracaine for transdermal analgesia |
CN102427792A (en) * | 2009-05-04 | 2012-04-25 | 扎斯制药公司 | Methods of treating pains associated with neuroma, nerve entrapment, and other conditions |
WO2011006012A1 (en) | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
US9919168B2 (en) | 2009-07-23 | 2018-03-20 | Palomar Medical Technologies, Inc. | Method for improvement of cellulite appearance |
US8404728B2 (en) | 2009-07-30 | 2013-03-26 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
WO2011057214A2 (en) | 2009-11-09 | 2011-05-12 | Neurogenetic Pharmaceuticals, Inc. | Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor |
US20110122058A1 (en) * | 2009-11-25 | 2011-05-26 | Louise Mohn | Inline control system for therapeutic pad |
US20110125204A1 (en) * | 2009-11-25 | 2011-05-26 | Mohn Louise | Electrostimulation pad with integrated temperature sensor |
US20110125205A1 (en) * | 2009-11-25 | 2011-05-26 | Mohn Louise | Thermostimulation system including multilayer pads with integrated temperature regulations |
US20110130796A1 (en) * | 2009-11-27 | 2011-06-02 | Mohn Louise | Thermostimulation methods using multilayer pads with integrated temperature regulation |
WO2011069002A1 (en) | 2009-12-02 | 2011-06-09 | Alquest Therapeutics, Inc. | Organoselenium compounds and uses thereof |
WO2011079313A1 (en) * | 2009-12-23 | 2011-06-30 | Map Pharmaceuticals, Inc. | Novel ergoline analogs |
US9693976B2 (en) | 2010-01-14 | 2017-07-04 | Crescita Therapeutics Inc. | Solid-forming local anesthetic formulations for pain control |
KR101784539B1 (en) | 2010-01-28 | 2017-10-11 | 랩터 파마슈티컬스 인코포레이티드 | Method for treating liver disorders with receptor associated protein (rap) peptide-fucosidase inhibitor conjugates |
JP4934210B2 (en) * | 2010-03-05 | 2012-05-16 | オカモト株式会社 | Skin laminate |
US9327105B2 (en) | 2010-03-26 | 2016-05-03 | Itrace Biomedical Inc. | Active transdermal drug delivery system and the method thereof |
AU2011239636A1 (en) | 2010-04-13 | 2012-11-22 | Najib Babul | Dermal pharmaceutical compositions of 1-Methyl-2',6'-pipecoloxylidide and method of use |
AR082319A1 (en) | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | PRODUCTION OF A HIGHLY ACTIVE PHOSPHORILED HUMAN N-ACETILGALACTOSAMINE-6-SULPHATASE AND ITS USES |
RU2583435C2 (en) | 2010-07-28 | 2016-05-10 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Peripherally restricted faah inhibitors |
EP2446865A1 (en) | 2010-10-28 | 2012-05-02 | Louise Mohn | Thermostimulation apparatus |
JP5976100B2 (en) | 2011-04-21 | 2016-08-23 | キュアマーク リミテッド ライアビリティ カンパニー | Compounds for the treatment of neuropsychiatric disorders |
GB201110632D0 (en) * | 2011-06-22 | 2011-08-03 | King S College London | Drug delivery formulations |
CN103827113A (en) | 2011-06-23 | 2014-05-28 | Map药物公司 | Novel fluoroergoline analogs |
AU2012278944B2 (en) | 2011-07-05 | 2015-09-17 | Bioasis Technologies Inc. | p97-antibody conjugates and methods of use |
EP3321281B1 (en) | 2011-08-05 | 2019-11-27 | biOasis Technologies Inc | P97 fragments with transfer activity |
MX354772B (en) | 2011-08-19 | 2018-03-21 | Univ California | Meta-substituted biphenyl peripherally restricted faah inhibitors. |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
US9700245B2 (en) | 2011-09-23 | 2017-07-11 | Itrace Biomedical Inc. | Transdermal analyte extraction and detection system and the method thereof |
WO2013049380A1 (en) | 2011-09-30 | 2013-04-04 | Teikoku Pharma Usa, Inc. | Transdermal patch disposal system |
WO2013049387A1 (en) | 2011-09-30 | 2013-04-04 | Teikoku Pharma Usa, Inc. | General medication disposal system |
EP2782567B1 (en) | 2011-11-22 | 2017-03-22 | The Regents of The University of California | Disubstituted beta-lactones as inhibitors of n-acylethanolamine acid amidase (naaa) |
CA2859173A1 (en) | 2011-12-19 | 2013-06-27 | Map Pharmaceuticals, Inc. | Novel iso-ergoline derivatives |
WO2013095708A1 (en) | 2011-12-21 | 2013-06-27 | Map Pharmaceuticals, Inc. | Novel neuromodulatory compounds |
EP2806940B1 (en) * | 2012-01-24 | 2019-05-22 | International Scientific PTY Ltd | Delivery device |
KR102183581B1 (en) | 2012-04-18 | 2020-11-27 | 싸이노슈어, 엘엘씨 | Picosecond laser apparatus and methods for treating target tissues with same |
SI2844637T1 (en) | 2012-05-02 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
EP2861562B1 (en) | 2012-06-14 | 2018-05-09 | Mayo Foundation For Medical Education And Research | Pyrazole derivatives as inhibitors of stat3 |
US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
US20140026905A1 (en) * | 2012-07-27 | 2014-01-30 | Nuvo Research Inc. | Apparatus and method of controlling the rate of nicotine delivery |
JP6433424B2 (en) | 2012-07-31 | 2018-12-05 | バイオアシス テクノロジーズ インコーポレイテッド | Dephosphorylated lysosomal storage disease protein and method of use thereof |
US9074186B2 (en) | 2012-08-15 | 2015-07-07 | Boston Medical Center Corporation | Production of red blood cells and platelets from stem cells |
SG11201504931SA (en) | 2012-12-21 | 2015-07-30 | Map Pharmaceuticals Inc | Novel methysergide derivatives |
US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
US9710607B2 (en) | 2013-01-15 | 2017-07-18 | Itrace Biomedical Inc. | Portable electronic therapy device and the method thereof |
US10179239B2 (en) | 2013-01-15 | 2019-01-15 | Itrace Biomedical Inc. | Personalized pain management treatments |
WO2014160438A1 (en) | 2013-03-13 | 2014-10-02 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
WO2014144547A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors |
EP2973894A2 (en) | 2013-03-15 | 2016-01-20 | Cynosure, Inc. | Picosecond optical radiation systems and methods of use |
WO2014144836A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors |
KR101482841B1 (en) | 2013-03-29 | 2015-01-21 | 가천대학교 산학협력단 | Microchip using wireless induction heating and drug delivery device comprising the same |
SG11201509982UA (en) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
WO2015008169A2 (en) * | 2013-07-04 | 2015-01-22 | Insuline Medical Ltd. | Device, system and method for delivery of a long-acting drug |
CA2937547A1 (en) * | 2014-01-22 | 2015-07-30 | Ekaabo Inc. | Portable device for treating external boils |
AU2015210612B2 (en) | 2014-02-03 | 2020-04-09 | Bioasis Technologies Inc. | P97 fusion proteins |
JP6605482B2 (en) | 2014-02-19 | 2019-11-13 | バイオアシス テクノロジーズ インコーポレイテッド | P97-IDS fusion protein |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
WO2015157313A1 (en) | 2014-04-07 | 2015-10-15 | The Regents Of The University Of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
WO2015168521A2 (en) | 2014-05-01 | 2015-11-05 | Bioasis Technologies, Inc. | P97-polynucleotide conjugates |
MA47849A (en) | 2014-05-28 | 2020-01-29 | Agenus Inc | ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE |
WO2016025129A1 (en) | 2014-08-14 | 2016-02-18 | Alhamadsheh Mamoun M | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
EP3229838B1 (en) | 2014-12-11 | 2020-09-09 | Pierre Fabre Medicament | Anti-c10orf54 antibodies and uses thereof |
EP3789039A1 (en) | 2014-12-22 | 2021-03-10 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
US9657020B2 (en) | 2015-01-20 | 2017-05-23 | Xoc Pharmaceuticals, Inc. | Ergoline compounds and uses thereof |
BR112017015510A2 (en) | 2015-01-20 | 2018-01-30 | Xoc Pharmaceuticals Inc | compound of formula (i), method of treatment and / or prevention, d2 receptor agonizing method in one individual, d3 receptor antagonizing method in one individual, 5-ht1d receptor agonizing method in one individual, 5-ht1a receptor agonization in one individual, selective 5-ht1d receptor agonizing method instead of 5-ht1b receptor in one individual, 5-ht2c re-receptor selective agonizing method instead of 5-ht2a or 5 receptor -ht2b in one individual, method of 5-ht2c receptor agonization in one individual, method of providing functional antagonist activity at 5-ht2b receptor or 5-ht7 receptor, and, method of providing functional antagonist activity at adrenergic receptors in one individual |
AU2016211330A1 (en) | 2015-01-28 | 2017-08-03 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
WO2016139482A1 (en) | 2015-03-03 | 2016-09-09 | Kymab Limited | Antibodies, uses & methods |
US20180156807A1 (en) | 2015-04-29 | 2018-06-07 | New York University | Method for treating high-grade gliomas |
SG10201913500TA (en) | 2015-05-29 | 2020-03-30 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
JP6981961B2 (en) | 2015-07-30 | 2021-12-17 | ホライズン オルファン エルエルシー | Fucosidase inhibitor |
EA201890630A1 (en) | 2015-09-01 | 2018-10-31 | Эйдженус Инк. | ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION |
DE102015219608B4 (en) | 2015-10-09 | 2018-05-03 | Clariant International Ltd | Universal pigment dispersions based on N-alkylglucamines |
US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
US10960013B2 (en) | 2016-03-04 | 2021-03-30 | East Carolina University | J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders |
EP3423041A4 (en) | 2016-03-04 | 2019-09-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
US10064855B2 (en) | 2016-03-08 | 2018-09-04 | Los Gatos Pharmaceuticals, Inc. | Composite nanoparticles and uses thereof |
JP2019513151A (en) | 2016-03-08 | 2019-05-23 | ロス ガトス ファーマスーティカルズ, インク.Los Gatos Pharmaceuticals, Inc. | Camptothecin derivatives and uses thereof |
US20170273821A1 (en) * | 2016-03-22 | 2017-09-28 | Elc Management Llc | Array Of Cutaneous Patches For Delivery And Heating Of Personal Care Products |
WO2017180794A1 (en) | 2016-04-13 | 2017-10-19 | Skyline Antiinfectives, Inc. | Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams |
ES2939373T3 (en) | 2016-05-13 | 2023-04-21 | Pasteur Institut | Inhibition of beta-2 nicotinic acetylcholine receptors to treat Alzheimer's disease pathology |
MX2018014387A (en) | 2016-05-27 | 2019-03-14 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof. |
KR20190039937A (en) | 2016-07-08 | 2019-04-16 | 스태튼 바이오테크놀로지 비.브이. | Anti-ApoC3 antibodies and methods of use thereof |
WO2018035281A1 (en) | 2016-08-17 | 2018-02-22 | North Carolina State University | Northern-southern route to synthesis of bacteriochlorins |
TW202246349A (en) | 2016-10-11 | 2022-12-01 | 美商艾吉納斯公司 | Anti-lag-3 antibodies and methods of use thereof |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
WO2018083538A1 (en) | 2016-11-07 | 2018-05-11 | Neuracle Scienc3 Co., Ltd. | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
US10106521B2 (en) | 2016-11-09 | 2018-10-23 | Phloronol, Inc. | Eckol derivatives, methods of synthesis and uses thereof |
US10836774B2 (en) | 2016-11-30 | 2020-11-17 | North Carolina State University | Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds |
CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
MX2019006340A (en) | 2016-12-07 | 2019-11-07 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof. |
WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
BR112019017260A2 (en) | 2017-02-17 | 2020-04-14 | Camris Int Inc | universal antivenom |
MX2019009764A (en) | 2017-02-17 | 2019-11-11 | Eidos Therapeutics Inc | Processes for preparing ag-10, its intermediates, and salts thereof. |
BR112019017241A2 (en) | 2017-04-13 | 2020-04-14 | Agenus Inc | anti-cd137 antibodies and methods of using them |
CN110506056A (en) | 2017-04-21 | 2019-11-26 | 斯塔滕生物技术有限公司 | Anti- APOC3 antibody and its application method |
EP3618863B1 (en) | 2017-05-01 | 2023-07-26 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
US10085999B1 (en) | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
WO2018223065A1 (en) | 2017-06-01 | 2018-12-06 | Xoc Pharmaceuticals, Inc. | Ergoline derivatives for use in medicine |
US10323289B2 (en) | 2017-06-26 | 2019-06-18 | Institut Pasteur | Treatments to eliminate HIV reservoirs and reduce viral load |
JP7076059B2 (en) | 2017-06-27 | 2022-05-27 | ニューラクル サイエンス カンパニー リミテッド | Anti-FAM19A5 antibody and its uses |
WO2019003164A1 (en) | 2017-06-27 | 2019-01-03 | Neuracle Science Co., Ltd. | Use of anti-fam19a5 antibodies for treating cancers |
EP3645044A4 (en) | 2017-06-27 | 2021-04-28 | Neuracle Science Co., Ltd | Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of glaucoma |
EP3645039A4 (en) | 2017-06-27 | 2021-05-05 | Neuracle Science Co., Ltd | Use of anti-fam19a5 antibodies for treating fibrosis |
ES2953032T3 (en) | 2017-09-01 | 2023-11-07 | Univ East Carolina | Ex vivo methods for the activation of immune cells |
CA3080103A1 (en) | 2017-10-31 | 2019-05-09 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
CA3092248A1 (en) | 2018-02-26 | 2019-08-29 | Mirko Mirkov | Q-switched cavity dumped sub-nanosecond laser |
US11389844B2 (en) | 2018-03-20 | 2022-07-19 | Verde Environmental Technologies, Inc. | Blister pack disposal system |
EP3768841A4 (en) | 2018-03-23 | 2021-12-08 | Eidos Therapeutics, Inc. | Methods of treating ttr amyloidosis using ag10 |
AU2019245429A1 (en) * | 2018-03-30 | 2020-10-15 | Northwestern University | Wireless and noninvasive epidermal electronics |
US11634484B2 (en) | 2018-04-24 | 2023-04-25 | Neuracle Science Co., Ltd. | Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain |
EP3801732A4 (en) | 2018-05-29 | 2022-04-27 | Morningside Venture Investments Limited | Drug delivery methods and systems |
BR112021000934A2 (en) | 2018-07-20 | 2021-04-27 | Pierre Fabre Medicament | receiver for sight |
BR112020026493A2 (en) | 2018-08-17 | 2021-03-23 | Eidos Therapeutics, Inc. | AG10 FORMULATIONS |
CN112969503A (en) | 2018-10-03 | 2021-06-15 | 斯塔滕生物技术有限公司 | Antibodies specific for human and cynomolgus macaques APOC3 and methods of use thereof |
CA3119341A1 (en) | 2018-11-16 | 2020-05-22 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
WO2020102695A1 (en) * | 2018-11-16 | 2020-05-22 | Cti (Assignment For Benefit Of Creditors) Llc | Thermally regulated transdermal drug delivery system |
WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
US11447468B2 (en) | 2019-02-06 | 2022-09-20 | Dice Alpha, Inc. | IL-17 ligands and uses thereof |
MA55080A (en) | 2019-02-26 | 2022-01-05 | Inspirna Inc | HIGH AFFINITY ANTI-MERTK ANTIBODIES AND ASSOCIATED USES |
CN114222803A (en) | 2019-05-20 | 2022-03-22 | 尼尔瓦纳科学股份有限公司 | Narrow emission dyes, compositions comprising the same, and methods of making and using the same |
WO2021021667A1 (en) * | 2019-07-26 | 2021-02-04 | Ryah Medtech, Inc. | Electronic patch for transdermal delivery of medical compositions |
US11680098B2 (en) | 2019-08-30 | 2023-06-20 | Agenus Inc. | Antibodies that specifically bind human CD96 |
WO2021055376A1 (en) | 2019-09-16 | 2021-03-25 | Dice Alpha, Inc. | Il-17a modulators and uses thereof |
US11865036B2 (en) | 2019-09-27 | 2024-01-09 | L'oreal | Integrated heater on facial skincare mask |
CN114945409A (en) | 2020-01-13 | 2022-08-26 | 新免疫技术有限公司 | Methods of treating tumors with combinations of IL-7 proteins and bispecific antibodies |
AU2021217373A1 (en) | 2020-02-05 | 2022-08-04 | Neoimmunetech, Inc. | Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
US20230398184A1 (en) | 2020-10-26 | 2023-12-14 | Neoimmunetech, Inc. | Methods of inducing stem cell mobilization |
KR20230104176A (en) | 2020-11-02 | 2023-07-07 | 네오이뮨텍, 인코퍼레이티드 | Use of interleukin-7 for treatment of coronavirus |
KR20230104175A (en) | 2020-11-05 | 2023-07-07 | 네오이뮨텍, 인코퍼레이티드 | Methods of Treating Tumors Using Combinations of IL-7 Protein and Nucleotide Vaccines |
US20220161011A1 (en) * | 2020-11-25 | 2022-05-26 | Jeff Dotson | Transdermal Delivery System |
AU2022232625A1 (en) | 2021-03-10 | 2023-09-28 | Dice Molecules Sv, Inc. | Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof |
IL309349A (en) | 2021-06-14 | 2024-02-01 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
WO2023130081A1 (en) | 2021-12-30 | 2023-07-06 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and vegf antagonist |
WO2023129577A1 (en) | 2022-01-03 | 2023-07-06 | Lilac Therapeutics, Inc. | Cyclic thiol prodrugs |
GB2619907A (en) | 2022-04-01 | 2023-12-27 | Kanna Health Ltd | Novel crystalline salt forms of mesembrine |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4747841A (en) * | 1985-03-19 | 1988-05-31 | Yasuro Kuratomi | Methods and instruments of moxibustion |
US5919479A (en) * | 1995-07-28 | 1999-07-06 | Zars, Inc. | Noninvasive dermal anesthetics |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB553587A (en) * | 1942-01-27 | 1943-05-27 | Clifford Bertram Sroka | Improvements in or relating to therapeutic plasters |
US3929131A (en) | 1975-01-09 | 1975-12-30 | Thomas L Hardwick | Bandage and method of using same |
DE2823174A1 (en) | 1977-07-06 | 1979-01-25 | Astra Laekemedel Ab | MEDICINAL PRODUCTS FOR THE PROPHYLACTIC TREATMENT OF POSTOPERATIVE DEEP VEIN THROMBOSIS |
SE7713618L (en) | 1977-12-01 | 1979-06-02 | Astra Laekemedel Ab | LOCAL ANESTHETIC MIXTURE |
US4230105A (en) * | 1978-11-13 | 1980-10-28 | Merck & Co., Inc. | Transdermal delivery of drugs |
US4286592A (en) | 1980-02-04 | 1981-09-01 | Alza Corporation | Therapeutic system for administering drugs to the skin |
US5651768A (en) | 1983-08-18 | 1997-07-29 | Drug Delivery Systems, Inc. | Transdermal drug applicator and electrodes therefor |
US5605536A (en) | 1983-08-18 | 1997-02-25 | Drug Delivery Systems Inc. | Transdermal drug applicator and electrodes therefor |
CH662740A5 (en) * | 1983-11-10 | 1987-10-30 | Innovadata Ag | DEVICE FOR CONTROLLED transdermal delivery of pharmaceutical agents. |
JPS60174716A (en) | 1984-02-21 | 1985-09-09 | Yamanouchi Pharmaceut Co Ltd | Medicinal patch |
GB2163956B (en) | 1984-09-08 | 1988-03-30 | Ile De France | Percutaneous anaesthetic composition for topical application |
US4693706A (en) | 1986-08-11 | 1987-09-15 | Mark L. Anderson | Two compartment mixing syringe |
DE3762480D1 (en) | 1986-08-23 | 1990-06-07 | Arno W Latzke | AGENT FOR APPLICATION OF TRANSDERMAL RESORBABLE ACTIVE SUBSTANCES. |
US4911707A (en) | 1987-02-13 | 1990-03-27 | Ciba-Geigy Corporation | Monolithic user-activated transdermal therapeutic system |
GB8712518D0 (en) | 1987-05-28 | 1987-07-01 | Univ Belfast | Unit-dose film composition |
DK158336C (en) | 1987-09-22 | 1990-10-01 | Coloplast As | CONNECTOR MATERIALS FOR THE TREATMENT OF WOUNDS AND TEMPLES FOR USE IN MANUFACTURING THEREOF |
US4830855A (en) | 1987-11-13 | 1989-05-16 | Landec Labs, Inc. | Temperature-controlled active agent dispenser |
JPH01122037U (en) * | 1988-02-12 | 1989-08-18 | ||
DE3806562A1 (en) | 1988-03-01 | 1989-09-14 | Alpha Therapeutic Gmbh | TWO CHAMBER SYRINGE WITH A FILLING OF ACTIVITY SENSITIVE HUMAN PROTEIN AS AN ACTIVE SUBSTANCE |
US4913957A (en) * | 1988-05-23 | 1990-04-03 | Kimberly-Clark Corporation | Thermal retaining fabric laminate |
DE3903794A1 (en) | 1989-02-09 | 1990-08-16 | Lohmann Therapie Syst Lts | THERAPEUTIC SYSTEM FOR THE TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE SUBSTANCES AND ITS USE |
US5217718A (en) | 1989-08-18 | 1993-06-08 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
US5276032A (en) | 1989-12-28 | 1994-01-04 | King O Newton | Vision aid and anesthetic composition |
US5229133A (en) | 1990-01-24 | 1993-07-20 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
US5279594A (en) | 1990-05-23 | 1994-01-18 | Jackson Richard R | Intubation devices with local anesthetic effect for medical use |
US5114411A (en) | 1990-11-19 | 1992-05-19 | Habley Medical Technology Corporation | Multi-chamber vial |
US5108710A (en) | 1990-11-26 | 1992-04-28 | Little Amy C | Transdermal patch holder |
US5580573A (en) | 1991-02-01 | 1996-12-03 | E. R. Squibb And Sons, Inc. | Temperature activated controlled release |
US5213129A (en) | 1991-03-25 | 1993-05-25 | Csb Limited Partnership | Fluid mixing device |
US5329976A (en) | 1991-12-09 | 1994-07-19 | Habley Medical Technology Corporation | Syringe-filling and medication mixing dispenser |
DK168420B1 (en) | 1992-03-27 | 1994-03-28 | Coloplast As | A heat dressing |
ATE160510T1 (en) | 1992-06-02 | 1997-12-15 | Alza Corp | DISPENSING DEVICE FOR ELECTRICALLY TRANSFERRING MEDICINAL PRODUCTS |
US5330452A (en) | 1993-06-01 | 1994-07-19 | Zook Gerald P | Topical medicating device |
US5534021A (en) | 1994-09-01 | 1996-07-09 | Dvoretzky; Israel | Heating pad for providing heat therapy |
ATE212819T1 (en) | 1995-06-29 | 2002-02-15 | Procter & Gamble | HEAT CELLS |
EP0835083B1 (en) | 1995-06-29 | 2003-07-16 | The Procter & Gamble Company | Elastic back wrap having diamond-shaped thermal pattern and anti-slip means |
JP3685263B2 (en) | 1995-06-29 | 2005-08-17 | ザ、プロクター、エンド、ギャンブル、カンパニー | Wing-shaped thermal neck wrap with positioning means |
US5728058A (en) | 1995-06-29 | 1998-03-17 | The Procter & Gamble Company | Elastic knee wrap |
US5906830A (en) | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
WO1997014473A1 (en) | 1995-10-18 | 1997-04-24 | Novartis Ag | Thermopile powered transdermal drug delivery device |
US5626571A (en) | 1995-11-30 | 1997-05-06 | The Procter & Gamble Company | Absorbent articles having soft, strong nonwoven component |
US5984995A (en) | 1996-03-29 | 1999-11-16 | The Procter & Gamble Company | Heat cells |
JP3545769B2 (en) | 1996-06-27 | 2004-07-21 | ザ、プロクター、エンド、ギャンブル、カンパニー | Thermal pad with common adhesive and oxygen permeable surface |
US5674270A (en) | 1996-06-27 | 1997-10-07 | The Procter & Gamble Company | Thermal pad having a common attachment and oxygen permeable side |
US5980562A (en) | 1996-07-26 | 1999-11-09 | The Procter & Gamble Company | Elastic back wrap having diamond-shaped thermal pattern and anti-slip means |
US5735889A (en) | 1996-11-08 | 1998-04-07 | The Procter & Gamble Company | Thermal neck wrap having means for position maintenance |
CN1154516C (en) | 1996-12-23 | 2004-06-23 | 普罗克特和甘保尔公司 | Adhesive for secure topical attachment to skin and comfortable removal |
AU738443B2 (en) | 1996-12-31 | 2001-09-20 | Procter & Gamble Company, The | Disposable elastic thermal back wrap and method for treatment of back pain |
US6020040A (en) | 1996-12-31 | 2000-02-01 | The Procter & Gamble Company | Thermal pack having a plurality of individual heat cells |
CA2276471A1 (en) | 1996-12-31 | 1998-07-09 | William Robert Ouellette | Disposable thermal neck wrap |
ATE347339T1 (en) | 1996-12-31 | 2006-12-15 | Procter & Gamble | A THERMAL PACK WITH MULTIPLE INDIVIDUAL HEAT CELLS |
US5860945A (en) | 1996-12-31 | 1999-01-19 | The Procter & Gamble Company | Disposable elastic thermal knee wrap |
US6019782A (en) | 1996-12-31 | 2000-02-01 | The Procter & Gamble Company | Disposable thermal body pad |
US5925072A (en) | 1996-12-31 | 1999-07-20 | The Procter & Gamble Company | Disposable elastic thermal back wrap |
US6048326A (en) | 1996-12-31 | 2000-04-11 | The Procter & Gamble Company | Disposable elastic thermal knee wrap |
US6042673A (en) | 1997-05-15 | 2000-03-28 | The Procter & Gamble Company | Method for making a flangeless seam for use in disposable articles |
US5906637A (en) | 1997-08-21 | 1999-05-25 | The Procter & Gamble Company | Disposable elastic thermal uniaxial joint wrap |
US5904710A (en) | 1997-08-21 | 1999-05-18 | The Procter & Gamble Company | Disposable elastic thermal body wrap |
USD403778S (en) | 1998-01-20 | 1999-01-05 | The Procter & Gamble Company | Neck wrap having thermal cells |
USD407822S (en) | 1998-01-20 | 1999-04-06 | The Procter & Gamble Company | Back wrap having thermal cells |
USD403779S (en) | 1998-01-20 | 1999-01-05 | The Procter & Gamble Company | Knee wrap having thermal cells |
USD409757S (en) | 1998-01-20 | 1999-05-11 | The Procter & Gamble Company | Back wrap having thermal cells |
USD418606S (en) | 1998-05-07 | 2000-01-04 | The Procter & Gamble Company | Neck wrap having thermal cells |
USD417283S (en) | 1998-05-07 | 1999-11-30 | The Procter & Gamble Company | Neck wrap having thermal cells |
USD412751S (en) | 1998-05-07 | 1999-08-10 | The Procter & Gamble Company | Back wrap having thermal cells |
USD407824S (en) | 1998-05-07 | 1999-04-06 | The Procter & Gamble Company | Neck wrap having thermal cells |
USD408923S (en) | 1998-05-07 | 1999-04-27 | The Procter & Gamble Company | Neck wrap having thermal cells |
US6261595B1 (en) * | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
-
2000
- 2000-02-29 US US09/515,722 patent/US6261595B1/en not_active Expired - Fee Related
-
2001
- 2001-02-28 WO PCT/US2001/006428 patent/WO2001064150A1/en not_active Application Discontinuation
- 2001-02-28 EP EP01911203A patent/EP1267764A4/en not_active Withdrawn
- 2001-05-24 US US09/864,472 patent/US6488959B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4747841A (en) * | 1985-03-19 | 1988-05-31 | Yasuro Kuratomi | Methods and instruments of moxibustion |
US5919479A (en) * | 1995-07-28 | 1999-07-06 | Zars, Inc. | Noninvasive dermal anesthetics |
Also Published As
Publication number | Publication date |
---|---|
US6488959B2 (en) | 2002-12-03 |
EP1267764A1 (en) | 2003-01-02 |
US6261595B1 (en) | 2001-07-17 |
EP1267764A4 (en) | 2006-11-29 |
US20020004066A1 (en) | 2002-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6261595B1 (en) | Transdermal drug patch with attached pocket for controlled heating device | |
EP1117356B1 (en) | Apparatus for improved administration of fentanyl and sufentanil | |
CA2345492C (en) | Methods and apparatus for improved administration of pharmaceutically active compounds | |
US6245347B1 (en) | Methods and apparatus for improved administration of pharmaceutically active compounds | |
US6756053B2 (en) | Controlled heat induced rapid delivery of pharmaceuticals from skin depot | |
US6955819B2 (en) | Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances | |
JP3547453B2 (en) | Device for improved non-invasive drug skin administration | |
JP2004510454A (en) | Febrile dressing | |
EP2392300A1 (en) | Skin patch laminate body | |
US20020114827A1 (en) | Methods and apparatus for improved administration of analgesics | |
JP2006326337A (en) | Controlled heat to regulate transdermal delivery of medical substance | |
EP1753412B1 (en) | Self-heating pharmaceutical patch |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001911203 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001911203 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001911203 Country of ref document: EP |